ACMG Carrier Screening Guidelines: Falling Short On Equity and Inclusion
By Katie Stoll and Robert Resta,
The DNA Exchange
| 07. 26. 2021
The American College of Medical Genetics and Genomics (ACMG) recently published a new Clinical Practice Resource that they proclaim recommends an “equitable approach for offering carrier screening to all individuals during pregnancy or preconception.”
We recognize the drawbacks of a screening program based solely on reported ancestry or ethnicity. And we understand that ensuring the same standard of carrier screening is available to all patients regardless of race or ethnic background addresses an important equity concern. However, the ACMG guidelines fall short in several areas:
- Addressing the benefits of carrier screening
- Questionable criteria for determining the severity of the included conditions
- A limited definition of inclusivity
- What choice patients should have in which conditions are or are not included in their personal screening.
The ACMG guidance is broad, calling for offering sequence-based population carrier screening for 113 genetic conditions to all patients who are pregnant or considering pregnancy. The rationale for expanded carrier screening according to the guideline is to allow for informed reproductive decisions. Specifically ACMG states that “reproductive decision making is the established metric for clinical utility of... see more
By Ian Sample and Hannah Devlin, The Guardian | 03.06.2023
The next generation of advanced genetic therapies raises profound medical and ethical issues that must be thrashed out to ensure the game-changing technology benefits patients and society, a group of world-leading experts has warned.
Medicines based on powerful gene editing...
By Natasha Mitchell, ABC (feat. CGS' Katie Hasson) | 03.17.2023
Chinese scientist Dr Jiankui He flouted the law and bioethics basics to create the world's first CRISPR gene edited babies. Now out of jail, he's on Twitter recruiting patients and raising funds for more trials, this time in adults not embryos. An...
By Robert Resta and Diane B. Paul, The DNA Exchange | 02.15.2023
This week in London, some 400 people from around the world – including scientists, bioethicists, patients, journalists, civil society groups, and the interested public – gathered for the Third International Summit on Human Genome Editing to discuss the current and future capabilities and challenges for the technology. Many others viewed the proceedings online.
Toward the end of the three-day event, the Summit organizing committee’s concluding statement appeared in each participant’s inbox. Committee chair Robin Lovell-Badge read it aloud. On reproductive...